Cargando…
Ethical Considerations for Unblinding and Vaccinating COVID-19 Vaccine Trial Placebo Group Participants
Autores principales: | Stoehr, Jenna Rose, Hamidian Jahromi, Alireza, Thomason, Clayton |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264198/ https://www.ncbi.nlm.nih.gov/pubmed/34249853 http://dx.doi.org/10.3389/fpubh.2021.702960 |
Ejemplares similares
-
Caution advised when considering “Exceptional” extended or single dose COVID-19 vaccination strategies
por: Hamidian Jahromi, Alireza, et al.
Publicado: (2021) -
Discussion of Race and Ethnicity in Real-World Data Sources: Considerations for Medical Device Regulatory Efforts
por: Hamidian Jahromi, Alireza, et al.
Publicado: (2021) -
Natural unblinding of BCG vaccination trials
por: Szigeti, Reka, et al.
Publicado: (2021) -
Considerations for resuming global surgery outreach programs during and after the coronavirus disease 2019 (COVID-19) pandemic
por: Stoehr, Jenna Rose, et al.
Publicado: (2021) -
Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group
por: Singh, Jerome Amir, et al.
Publicado: (2021)